- Home
- CDTX
as 04-02-2025 4:00pm EST
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 259.0M | IPO Year: | 2015 |
| Target Price: | $38.00 | AVG Volume (30 days): | 148.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -26.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.00 - $28.42 | Next Earning Date: | 05-14-2025 |
| Revenue: | $1,275,000 | Revenue Growth: | -94.52% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cidara Therapeutics Inc. (CDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ward Shane | CDTX | COO & CLO | Mar 11 '25 | Sell | $21.96 | 1,664 | $36,542.11 | 14,674 | |
| Tari Leslie | CDTX | CHIEF SCIENTIFIC OFFICER | Mar 11 '25 | Sell | $21.96 | 1,773 | $38,939.69 | 16,215 |
Latest Cidara Therapeutics Inc. News
CDTX Breaking Stock News: Dive into CDTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
a day ago
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Zacks
13 days ago
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
TipRanks
15 days ago
Cidara Therapeutics to present on CD388 at ICAR 2025
GlobeNewswire
15 days ago
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
GlobeNewswire
16 days ago
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
GlobeNewswire
17 days ago
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Associated Press Finance
a month ago
Cidara Therapeutics: Q4 Earnings Snapshot
Compare CDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDTX Cidara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.